市場調査レポート

商品コード

1458419

ERCPの世界市場：治療法別、製品別、適応症別、エンドユーザー別、地域別の機会および予測 (2017年～2031年)

ERCP Market Assessment, By Treatment, By Product, By Disease Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年04月01日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 229 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 707,130円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 895,698円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,288,548円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のERCPの市場規模は、予測期間の2024年～2031年に7.41%のCAGRで拡大し、2023年の16億5,000万米ドルから2031年には29億2,000万米ドルに成長すると予測されています。世界のERCP市場を形成する要因はさまざまです。これには、技術の進歩、トレーニング施設の設置、内視鏡機器の使用の増加、高度な内視鏡可視化の需要の増加、消化器・肝臓疾患センターの設立などが含まれます。

ERCP技術や機器が革新的であり続け、診断・治療能力を向上させるためには、継続的な技術進歩が不可欠です。世界のERCP市場が成長しているのは、こうした市場開発が治療の選択肢を広げると同時に、患者ケアと手技の成果を向上させているからです。ERCP手技を実施するヘルスケア従事者の熟練度を向上させるには、トレーニング施設を設立する必要があります。これらの施設は実地訓練を行い、専門知識を育成し、患者の安全と幸福のための厳格なガイドラインを維持するため、質の高い医療を保証するために不可欠です。こうしたトレーニングセンターは、世界のERCP市場の拡大に貢献しています。

世界のERCP市場は、ERCP治療の強化・拡大に不可欠な内視鏡や可視化システムなどの内視鏡機器の使用拡大により、急成長が見込まれています。これらのツールは診断と治療の精度を向上させ、患者の予後を改善し、肝臓および消化管疾患の管理を前進させます。洗練された内視鏡可視化ツールに対する需要の増加は、ERCP処置中の患者の診断と治療の精度を向上させます。このような需要の高まりは、ヘルスケア従事者がより正確な診断とカスタマイズされた治療を提供できるようにすることで患者の転帰を改善し、ひいては患者ケアの水準を高め、世界のERCP市場の拡大を後押ししています。

肝臓および消化器疾患の専門センターの設立は、ERCPの知識、調査、包括的な治療を促進します。これらの施設は患者ケアの向上のための拠点として機能し、複雑な肝疾患や消化器疾患の診断と治療におけるチームワークを促進し、ERCPの世界市場拡大に重要な役割を果たしています。

当レポートでは、世界のERCP市場について調査し、市場の概要とともに、治療法別、製品別、適応症別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 2.Global ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 3.Global ERCP Market Share (%), By Treatment, 2017-2031F
Figure 4.Global ERCP Market Share (%), By Product, 2017-2031F
Figure 5.Global ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 6.Global ERCP Market Share (%), By End-user, 2017-2031F
Figure 7.Global ERCP Market Share (%), By Region, 2017-2031F
Figure 8.North America ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 9.North America ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 10.North America ERCP Market Share (%), By Treatment, 2017-2031F
Figure 11.North America ERCP Market Share (%), By Product, 2017-2031F
Figure 12.North America ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 13.North America ERCP Market Share (%), By End-user, 2017-2031F
Figure 14.North America ERCP Market Share (%), By Country, 2017-2031F
Figure 15.United States ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 16.United States ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 17.United States ERCP Market Share (%), By Treatment, 2017-2031F
Figure 18.United States ERCP Market Share (%), By Product, 2017-2031F
Figure 19.United States ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 20.United States ERCP Market Share (%), By End-user, 2017-2031F
Figure 21.Canada ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 22.Canada ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 23.Canada ERCP Market Share (%), By Treatment, 2017-2031F
Figure 24.Canada ERCP Market Share (%), By Product, 2017-2031F
Figure 25.Canada ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 26.Canada ERCP Market Share (%), By End-user, 2017-2031F
Figure 27.Mexico ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 28.Mexico ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 29.Mexico ERCP Market Share (%), By Treatment, 2017-2031F
Figure 30.Mexico ERCP Market Share (%), By Product, 2017-2031F
Figure 31.Mexico ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 32.Mexico ERCP Market Share (%), By End-user, 2017-2031F
Figure 33.Europe ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 34.Europe ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 35.Europe ERCP Market Share (%), By Treatment, 2017-2031F
Figure 36.Europe ERCP Market Share (%), By Product, 2017-2031F
Figure 37.Europe ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 38.Europe ERCP Market Share (%), By End-user, 2017-2031F
Figure 39.Europe ERCP Market Share (%), By Country, 2017-2031F
Figure 40.Germany ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 41.Germany ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 42.Germany ERCP Market Share (%), By Treatment, 2017-2031F
Figure 43.Germany ERCP Market Share (%), By Product, 2017-2031F
Figure 44.Germany ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 45.Germany ERCP Market Share (%), By End-user, 2017-2031F
Figure 46.France ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 47.France ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 48.France ERCP Market Share (%), By Treatment, 2017-2031F
Figure 49.France ERCP Market Share (%), By Product, 2017-2031F
Figure 50.France ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 51.France ERCP Market Share (%), By End-user, 2017-2031F
Figure 52.Italy ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 53.Italy ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 54.Italy ERCP Market Share (%), By Treatment, 2017-2031F
Figure 55.Italy ERCP Market Share (%), By Product, 2017-2031F
Figure 56.Italy ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 57.Italy ERCP Market Share (%), By End-user, 2017-2031F
Figure 58.United Kingdom ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 59.United Kingdom ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 60.United Kingdom ERCP Market Share (%), By Treatment, 2017-2031F
Figure 61.United Kingdom ERCP Market Share (%), By Product, 2017-2031F
Figure 62.United Kingdom ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 63.United Kingdom ERCP Market Share (%), By End-user, 2017-2031F
Figure 64.Russia ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 65.Russia ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 66.Russia ERCP Market Share (%), By Treatment, 2017-2031F
Figure 67.Russia ERCP Market Share (%), By Product, 2017-2031F
Figure 68.Russia ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 69.Russia ERCP Market Share (%), By End-user, 2017-2031F
Figure 70.Netherlands ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 71.Netherlands ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 72.Netherlands ERCP Market Share (%), By Treatment, 2017-2031F
Figure 73.Netherlands ERCP Market Share (%), By Product, 2017-2031F
Figure 74.Netherlands ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 75.Netherlands ERCP Market Share (%), By End-user, 2017-2031F
Figure 76.Spain ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 77.Spain ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 78.Spain ERCP Market Share (%), By Treatment, 2017-2031F
Figure 79.Spain ERCP Market Share (%), By Product, 2017-2031F
Figure 80.Spain ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 81.Spain ERCP Market Share (%), By End-user, 2017-2031F
Figure 82.Turkey ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 83.Turkey ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 84.Turkey ERCP Market Share (%), By Treatment, 2017-2031F
Figure 85.Turkey ERCP Market Share (%), By Product, 2017-2031F
Figure 86.Turkey ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 87.Turkey ERCP Market Share (%), By End-user, 2017-2031F
Figure 88.Poland ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 89.Poland ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 90.Poland ERCP Market Share (%), By Treatment, 2017-2031F
Figure 91.Poland ERCP Market Share (%), By Product, 2017-2031F
Figure 92.Poland ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 93.Poland ERCP Market Share (%), By End-user, 2017-2031F
Figure 94.South America ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 95.South America ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 96.South America ERCP Market Share (%), By Treatment, 2017-2031F
Figure 97.South America ERCP Market Share (%), By Product, 2017-2031F
Figure 98.South America ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 99.South America ERCP Market Share (%), By End-user, 2017-2031F
Figure 100.South America ERCP Market Share (%), By Country, 2017-2031F
Figure 101.Brazil ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 102.Brazil ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 103.Brazil ERCP Market Share (%), By Treatment, 2017-2031F
Figure 104.Brazil ERCP Market Share (%), By Product, 2017-2031F
Figure 105.Brazil ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 106.Brazil ERCP Market Share (%), By End-user, 2017-2031F
Figure 107.Argentina ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 108.Argentina ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 109.Argentina ERCP Market Share (%), By Treatment, 2017-2031F
Figure 110.Argentina ERCP Market Share (%), By Product, 2017-2031F
Figure 111.Argentina ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 112.Argentina ERCP Market Share (%), By End-user, 2017-2031F
Figure 113.Asia-Pacific ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 114.Asia-Pacific ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 115.Asia-Pacific ERCP Market Share (%), By Treatment, 2017-2031F
Figure 116.Asia-Pacific ERCP Market Share (%), By Product, 2017-2031F
Figure 117.Asia-Pacific ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 118.Asia-Pacific ERCP Market Share (%), By End-user, 2017-2031F
Figure 119.Asia-Pacific ERCP Market Share (%), By Country, 2017-2031F
Figure 120.India ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 121.India ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 122.India ERCP Market Share (%), By Treatment, 2017-2031F
Figure 123.India ERCP Market Share (%), By Product, 2017-2031F
Figure 124.India ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 125.India ERCP Market Share (%), By End-user, 2017-2031F
Figure 126.China ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 127.China ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 128.China ERCP Market Share (%), By Treatment, 2017-2031F
Figure 129.China ERCP Market Share (%), By Product, 2017-2031F
Figure 130.China ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 131.China ERCP Market Share (%), By End-user, 2017-2031F
Figure 132.Japan ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 133.Japan ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 134.Japan ERCP Market Share (%), By Treatment, 2017-2031F
Figure 135.Japan ERCP Market Share (%), By Product, 2017-2031F
Figure 136.Japan ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 137.Japan ERCP Market Share (%), By End-user, 2017-2031F
Figure 138.Australia ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 139.Australia ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 140.Australia ERCP Market Share (%), By Treatment, 2017-2031F
Figure 141.Australia ERCP Market Share (%), By Product, 2017-2031F
Figure 142.Australia ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 143.Australia ERCP Market Share (%), By End-user, 2017-2031F
Figure 144.Vietnam ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 145.Vietnam ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 146.Vietnam ERCP Market Share (%), By Treatment, 2017-2031F
Figure 147.Vietnam ERCP Market Share (%), By Product, 2017-2031F
Figure 148.Vietnam ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 149.Vietnam ERCP Market Share (%), By End-user, 2017-2031F
Figure 150.South Korea ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 151.South Korea ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 152.South Korea ERCP Market Share (%), By Treatment, 2017-2031F
Figure 153.South Korea ERCP Market Share (%), By Product, 2017-2031F
Figure 154.South Korea ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 155.South Korea ERCP Market Share (%), By End-user, 2017-2031F
Figure 156.Indonesia ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 157.Indonesia ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 158.Indonesia ERCP Market Share (%), By Treatment, 2017-2031F
Figure 159.Indonesia ERCP Market Share (%), By Product, 2017-2031F
Figure 160.Indonesia ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 161.Indonesia ERCP Market Share (%), By End-user, 2017-2031F
Figure 162.Philippines ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 163.Philippines ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 164.Philippines ERCP Market Share (%), By Treatment, 2017-2031F
Figure 165.Philippines ERCP Market Share (%), By Product, 2017-2031F
Figure 166.Philippines ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 167.Philippines ERCP Market Share (%), By End-user, 2017-2031F
Figure 168.Middle East & Africa ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 169.Middle East & Africa ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 170.Middle East & Africa ERCP Market Share (%), By Treatment, 2017-2031F
Figure 171.Middle East & Africa ERCP Market Share (%), By Product, 2017-2031F
Figure 172.Middle East & Africa ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 173.Middle East & Africa ERCP Market Share (%), By End-user, 2017-2031F
Figure 174.Middle East & Africa ERCP Market Share (%), By Country, 2017-2031F
Figure 175.Saudi Arabia ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 176.Saudi Arabia ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 177.Saudi Arabia ERCP Market Share (%), By Treatment, 2017-2031F
Figure 178.Saudi Arabia ERCP Market Share (%), By Product, 2017-2031F
Figure 179.Saudi Arabia ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 180.Saudi Arabia ERCP Market Share (%), By End-user, 2017-2031F
Figure 181.UAE ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 182.UAE ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 183.UAE ERCP Market Share (%), By Treatment, 2017-2031F
Figure 184.UAE ERCP Market Share (%), By Product, 2017-2031F
Figure 185.UAE ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 186.UAE ERCP Market Share (%), By End-user, 2017-2031F
Figure 187.South Africa ERCP Market, By Value, In USD Billion, 2017-2031F
Figure 188.South Africa ERCP Market, By Volume, In Million Units, 2017-2031F
Figure 189.South Africa ERCP Market Share (%), By Treatment, 2017-2031F
Figure 190.South Africa ERCP Market Share (%), By Product, 2017-2031F
Figure 191.South Africa ERCP Market Share (%), By Disease Indication, 2017-2031F
Figure 192.South Africa ERCP Market Share (%), By End-user, 2017-2031F
Figure 193.By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194.By Product Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195.By Disease Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196.By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11216

The global ERCP market is projected to witness a CAGR of 7.41% during the forecast period 2024-2031, growing from USD 1.65 billion in 2023 to USD 2.92 billion in 2031. Various factors shape the global ERCP market. These include technological advancements, setting up of training facilities, growing use of endoscopy devices, increasing demand for advanced endoscopic visualization, and establishing gastrointestinal and liver disease centers.

For ERCP techniques and equipment to remain innovative and improve diagnostic and therapeutic capabilities, ongoing technological advancements are essential. The global ERCP market is growing because of these developments, which also improve patient care and procedural outcomes while extending therapy options. To improve the proficiency of healthcare personnel in carrying out ERCP procedures, training facilities must be established. These facilities are essential to ensure high-quality care because they provide hands-on training, foster expertise, and maintain strict guidelines for patient safety and well-being. These training centers contribute to the expansion of the global ERCP market.

The global ERCP market is expected to grow at a rapid pace due to the growing use of endoscopy instruments, including endoscopes and visualization systems, which are essential for enhancing and expanding ERCP treatments. These tools improve the precision of diagnosis and treatment, improving patient outcomes and advancing the management of liver and gastrointestinal disorders. The increasing demand for sophisticated endoscopic visualization tools improves patient diagnosis and treatment precision during ERCP procedures. This growing demand improves patient outcomes by enabling healthcare practitioners to provide more accurate diagnoses and customized treatments, which, in turn, raises the standard of patient care and drives the expansion of the global ERCP market.

The creation of specialized centers for liver and gastrointestinal disorders fosters knowledge, investigation, and comprehensive treatment of ERCP. These facilities serve as hubs for improved patient care, promote teamwork in the diagnosis and treatment of complex hepatic and gastrointestinal problems, and play a significant role in the expansion of the global ERCP market.

For example, in February 2024, a cutting-edge center for gastrointestinal and liver disorders was opened by prominent private healthcare services company Burjeel Holdings. The facility offers the most cutting-edge medical procedures available. The pancreas, liver, gallbladder, colon, esophagus, stomach, and small intestine are among the ailments that the center focuses on preventing, diagnosing, and treating.

Technological Advancements

Artificial Intelligence (AI) is one of the key technological developments driving the growth of the global ERCP market. AI systems aim to simulate and enhance human intellect to support ERCP procedures by solving problems and making decisions. AI is revolutionizing healthcare delivery by improving diagnostic precision, treatment accuracy, and overall patient outcomes. This allows healthcare practitioners to give patients more effective and personalized care. This wave of AI-powered advancements keeps changing ERCP procedures and gives medical staff better tools to treat patients as best they can, which is a big step forward for the management of gastrointestinal and liver diseases.

AnX Robotica, a trailblazer in cutting-edge gastrointestinal visualization technology, for example, announced in January 2024 that the FDA had cleared NaviCam ProScan for use. ProScan is the first AI-assisted reading tool created to support small bowel capsule endoscopy reviewers for adult patients whose capsule endoscopy images were taken for suspected small intestine hemorrhage. The FDA approved ProScan through the stringent De Novo Submission Process.

Setting Up Training Facilities

The creation of training centers by public and commercial entities has a significant impact on the growth of the global ERCP market. The goal of this partnership is to enhance the skills of medical professionals in executing ERCP procedures, ensuring that patients receive the best possible care. These initiatives enhance knowledge, research, and comprehensive patient care in the field of managing gastrointestinal and liver diseases through these specialized training spaces. The training facilities are designed to help gastroenterologists become more proficient in basic and advanced GI endoscopy, including endoscopic ultrasound. Through these endeavors, newly developed technologies become more widely available and can be employed effectively to fulfill intended purposes.

For example, Fujifilm India and the Department of Gastroenterology at Yashoda Group of Hospitals in Hyderabad formally partnered in September 2023 to develop a training and research facility. Physicians from the Asia-Pacific region are offered extensive training and observation programs in the training facility.

Growing Use of Endoscopy Devices

The global ERCP market is expanding due to the increasing use of advanced endoscopic technologies with improved performance. Patients eventually gain from these advancements because they increase the precision of diagnosis and therapy. The growing prevalence of cancer, government spending on medical research, and an emphasis on advancing endoscopic methods are all factors contributing to the market's expansion. The field of managing gastrointestinal and liver diseases has been significantly shaped by the advancement and widespread use of sophisticated endoscopic equipment.

For instance, in October 2023, Olympus, a manufacturer of medical technology, unveiled its cutting-edge EVIS X1 endoscopic equipment for gastrointestinal (GI) professionals. During the endoscopic screening, the EVIS X1 endoscopy system's Texture and Colour Enhancement Imaging technology improves image color and texture to make lesions and polyps easier to see.

Increasing Demand for Advanced Endoscopic Visualization

The global ERCP market is expanding due to the rising need for sophisticated endoscopic visualization equipment. The components of the endoscopy visualization system include video processors, displays, printers, insufflators, and a light source. Medical equipment like endoscopy devices is used to diagnose disorders by looking at interior organs. Devices that support the visualization and interpretation of endoscopic images are referred to as endoscopy visualization systems and components. The visualization devices enhance the vision during endoscopy and result in an increased efficiency and outcome of the procedure.

For example, in January 2024, OMNIVISION, a developer of semiconductor solutions, including advanced digital imaging and touch display technology, and EndoQuest Robotics, a medical device company leading the development of novel endoluminal robotic technologies, partnered to integrate OMNIVISION's OCHFA CameraCubeChip into EndoQuest's Flexible Robotic System to address the unmet needs in GI and other endoluminal surgeries.

Established European Market

Europe is a major player in the global ERCP business, with France, Germany, and the United Kingdom at the forefront. Important drivers of market expansion include the aging population in Germany and the high level of healthcare spending in France. The sophisticated healthcare infrastructure in Europe and the calculated efforts of industry participants are driving the market's expansion. The region's adoption of cutting-edge technologies and investments in healthcare professional training has further strengthened this trend, underscoring Europe's important influence on the development of ERCP treatments.

For example, in April 2023, Olympus, a Japanese company that produces items for reprography and optics, launched EndoClot Adhesive (ECA), EndoClot Polysaccharide Hemostatic Spray (PHS), and EndoClot Submucosal Injection Solution (SIS) in Europe. EndoClot Plus, Inc. (EPI) created this cutting-edge portfolio; in December 2022, it extended its distribution contract with Olympus. During endoscopic submucosal dissection or resection during gastrointestinal procedures, the EndoClot portfolio aids hemostasis and lifting.

Future Market Scenario (2024 - 2031F)

In growing economies like China, Brazil, and India, the worldwide ERCP market is expanding significantly. Several variables, such as the growth of sophisticated healthcare infrastructure, increased disposable incomes, and the increasing focus on advanced medical procedures in these areas, are responsible for this expansion.

Personalised medicine is where the ERCP market is going in the future. Personalized medicine in ERCP seeks to improve overall patient care quality and optimize results by customizing therapies for each patient.

The increasing prevalence of telemedicine and remote healthcare services is expected to drive the expansion of the global ERCP market, as the integration of ERCP procedures into these platforms is expected to increase.

The global ERCP market is likely to be impacted in the future by anticipated regulatory changes and improvements in global healthcare policies.

Key Players Landscape and Outlook

Businesses looking to expand their market position through mergers and acquisitions are actively attempting to join the global ERCP market. These calculated actions are intended to strengthen competitive positions, get access to new technology, and grow market share. Companies can pool resources, use synergies, and combine strengths through these collaborations to promote innovation and industry growth. This trend demonstrates a dynamic business climate where companies are actively looking for ways to collaborate, come together, and change to suit the ever-evolving demands of the global ERCP market.

For example, in February 2023, Olympus announced that it would purchase Taewoong Medical, a medical device manufacturer based in Korea that makes stents, for USD 370 million. Taewoong Medical produces medical equipment, such as metallic stents, for the GI. Through the acquisition, Olympus hopes to improve the capabilities of its GI endotherapy portfolio.

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global ERCP Market Outlook, 2017-2031F

4.1.Market Size & Forecast
- 4.1.1.By Value
- 4.1.2.By Volume
4.2.By Treatment
- 4.2.1.Balloon Dilation
- 4.2.2.Stent Insertion
- 4.2.3.Sphincterotomy
- 4.2.4.Stone Removal
- 4.2.5.Biopsy
4.3.By Product
- 4.3.1.Endotherapy Devices
  - 4.3.1.1.Balloons
  - 4.3.1.2.Band Ligator
  - 4.3.1.3.Baskets
  - 4.3.1.4.Clips
  - 4.3.1.5.Forceps
  - 4.3.1.6.Guidewires
  - 4.3.1.7.Needles
  - 4.3.1.8.Snares
  - 4.3.1.9.Sphincterotomes
  - 4.3.1.10.Stents
- 4.3.2.Endoscopes
- 4.3.3.Visualization Systems
- 4.3.4.Energy Devices
- 4.3.5.Others
4.4.By Disease Indication
- 4.4.1.Pancreatitis
- 4.4.2.Crohn's Disease
- 4.4.3.Gastroesophageal Reflux Disease
- 4.4.4.GI Cancer
- 4.4.5.Barrett's Esophagus
- 4.4.6.Peptic Ulcer Disease
- 4.4.7.Others
4.5.By End-user
- 4.5.1.Hospitals
- 4.5.2.Diagnostic Laboratories
- 4.5.3.Ambulatory Surgical Centers & Clinics
- 4.5.4.Others
4.6.By Region
- 4.6.1.North America
- 4.6.2.Europe
- 4.6.3.Asia-Pacific
- 4.6.4.South America
- 4.6.5.Middle East and Africa
4.7.By Company Market Share (%), 2023

5.Global ERCP Market Outlook, By Region, 2017-2031F

5.1.North America*
- 5.1.1.Market Size & Forecast
  - 5.1.1.1.By Value
  - 5.1.1.2.By Volume
- 5.1.2.By Treatment
  - 5.1.2.1.Balloon Dilation
  - 5.1.2.2.Stent Insertion
  - 5.1.2.3.Sphincterotomy
  - 5.1.2.4.Stone Removal
  - 5.1.2.5.Biopsy
- 5.1.3.By Product
  - 5.1.3.1.Endotherapy Devices
  - 5.1.3.1.1.Balloons
  - 5.1.3.1.2.Band Ligator
  - 5.1.3.1.3.Baskets
  - 5.1.3.1.4.Clips
  - 5.1.3.1.5.Forceps
  - 5.1.3.1.6.Guidewires
  - 5.1.3.1.7.Needles
  - 5.1.3.1.8.Snares
  - 5.1.3.1.9.Sphincterotomes
  - 5.1.3.1.10.Stents
  - 5.1.3.2.Endoscopes
  - 5.1.3.3.Visualization Systems
  - 5.1.3.4.Energy Devices
  - 5.1.3.5.Others
- 5.1.4.By Disease Indication
  - 5.1.4.1.Pancreatitis
  - 5.1.4.2.Crohn's Disease
  - 5.1.4.3.Gastroesophageal Reflux Disease
  - 5.1.4.4.GI Cancer
  - 5.1.4.5.Barrett's Esophagus
  - 5.1.4.6.Peptic Ulcer Disease
  - 5.1.4.7.Others
- 5.1.5.By End-user
  - 5.1.5.1.Hospitals
  - 5.1.5.2.Diagnostic Laboratories
  - 5.1.5.3.Ambulatory Surgical Centers & Clinics
  - 5.1.5.4.Others
- 5.1.6.United States*
  - 5.1.6.1.Market Size & Forecast
  - 5.1.6.1.1.By Value
  - 5.1.6.1.2.By Volume
  - 5.1.6.2.By Treatment
  - 5.1.6.2.1.Balloon Dilation
  - 5.1.6.2.2.Stent Insertion
  - 5.1.6.2.3.Sphincterotomy
  - 5.1.6.2.4.Stone Removal
  - 5.1.6.2.5.Biopsy
  - 5.1.6.3.By Product
  - 5.1.6.3.1.Endotherapy Devices
  - 5.1.6.3.1.1.Balloons
  - 5.1.6.3.1.2.Band Ligator
  - 5.1.6.3.1.3.Baskets
  - 5.1.6.3.1.4.Clips
  - 5.1.6.3.1.5.Forceps
  - 5.1.6.3.1.6.Guidewires
  - 5.1.6.3.1.7.Needles
  - 5.1.6.3.1.8.Snares
  - 5.1.6.3.1.9.Sphincterotomes
  - 5.1.6.3.1.10.Stents
  - 5.1.6.3.2.Endoscopes
  - 5.1.6.3.3.Visualization Systems
  - 5.1.6.3.4.Energy Devices
  - 5.1.6.3.5.Others
  - 5.1.6.4.By Disease Indication
  - 5.1.6.4.1.Pancreatitis
  - 5.1.6.4.2.Crohn's Disease
  - 5.1.6.4.3.Gastroesophageal Reflux Disease
  - 5.1.6.4.4.GI Cancer
  - 5.1.6.4.5.Barrett's Esophagus
  - 5.1.6.4.6.Peptic Ulcer Disease
  - 5.1.6.4.7.Others
  - 5.1.6.5.By End-user
  - 5.1.6.5.1.Hospitals
  - 5.1.6.5.2.Diagnostic Laboratories
  - 5.1.6.5.3.Ambulatory Surgical Centers & Clinics
  - 5.1.6.5.4.Others
- 5.1.7.Canada
- 5.1.8.Mexico

All segments will be provided for all regions and countries covered

5.2.Europe
- 5.2.1.Germany
- 5.2.2.France
- 5.2.3.Italy
- 5.2.4.United Kingdom
- 5.2.5.Russia
- 5.2.6.Netherlands
- 5.2.7.Spain
- 5.2.8.Turkey
- 5.2.9.Poland
5.3.Asia-Pacific
- 5.3.1.India
- 5.3.2.China
- 5.3.3.Japan
- 5.3.4.Australia
- 5.3.5.Vietnam
- 5.3.6.South Korea
- 5.3.7.Indonesia
- 5.3.8.Philippines
5.4.South America
- 5.4.1.Brazil
- 5.4.2.Argentina
5.5.Middle East & Africa
- 5.5.1.Saudi Arabia
- 5.5.2.UAE
- 5.5.3.South Africa

6.Market Mapping, 2023

6.1.By Treatment
6.2.By Product
6.3.By Disease Indication
6.4.By End-user
6.5.By Region

7.Macro Environment and Industry Structure

7.1.Demand Supply Analysis
7.2.Import Export Analysis
7.3.Value Chain Analysis
7.4.PESTEL Analysis
- 7.4.1.Political Factors
- 7.4.2.Economic System
- 7.4.3.Social Implications
- 7.4.4.Technological Advancements
- 7.4.5.Environmental Impacts
- 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5.Porter's Five Forces Analysis
- 7.5.1.Supplier Power
- 7.5.2.Buyer Power
- 7.5.3.Substitution Threat
- 7.5.4.Threat from New Entrant
- 7.5.5.Competitive Rivalry

8.Market Dynamics

8.1.Growth Drivers
8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

9.1.Clinical Trials
9.2.Patent Landscape
9.3.Regulatory Approvals
9.4.Innovations/Emerging Technologies

10.Key Players Landscape

10.1.Competition Matrix of Top Five Market Leaders
10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4.SWOT Analysis (For Five Market Players)
10.5.Patent Analysis (If Applicable)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

13.1.Olympus Corporation
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
13.2.Hoya Corporation
13.3.Fujifilm Holdings Corporation
13.4.Boston Scientific Corporation
13.5.Johnson & Johnson
13.6.Medtronic plc
13.7.Conmed Corporation
13.8.B. Braun Melsungen AG
13.9.Karl Storz SE & Co KG
13.10.Boston Scientific Corporation

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

ERCPの世界市場：治療法別、製品別、適応症別、エンドユーザー別、地域別の機会および予測 (2017年～2031年)

ERCP Market Assessment, By Treatment, By Product, By Disease Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のERCP市場の見通し、2017年～2031年

第5章世界のERCP市場の見通し、地域別、2017年～2031年

第6章 2023年の市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制枠組みとイノベーション

第10章主要参入企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要参入企業の見通し

第14章戦略的提言

第15章お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global ERCP Market Outlook, 2017-2031F

5.Global ERCP Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

ERCPの世界市場：治療法別、製品別、適応症別、エンドユーザー別、地域別の機会および予測 (2017年～2031年)

ERCP Market Assessment, By Treatment, By Product, By Disease Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のERCP市場の見通し、2017年～2031年

第5章 世界のERCP市場の見通し、地域別、2017年～2031年

第6章 2023年の市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制枠組みとイノベーション

第10章 主要参入企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要参入企業の見通し

第14章 戦略的提言

第15章 お問い合わせと免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global ERCP Market Outlook, 2017-2031F

5.Global ERCP Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のERCP市場の見通し、2017年～2031年

第5章世界のERCP市場の見通し、地域別、2017年～2031年

第7章マクロ環境と産業構造

第8章市場力学

第9章規制枠組みとイノベーション

第10章主要参入企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要参入企業の見通し

第14章戦略的提言

第15章お問い合わせと免責事項